Evidence map›Paper›PMID 39554741›Full record

ArticleWorld journal of gastrointestinal oncology2024

Present and prospect of transarterial chemoembolization combined with tyrosine kinase inhibitor and PD-1 inhibitor for unresectable hepatocellular carcinoma.

Rui Zhang, Yan-Hui Liu, Yu Li, Nan-Nan Li, Zheng Li

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastrointestinal oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Rui ZhangDepartment of Pharmacy, The Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei 230011, Anhui Province, China.
Yan-Hui LiuDepartment of Clinical Pharmacy, Anhui Provincial Children's Hospital, Hefei 230000, Anhui Province, China.
Yu LiDepartment of Pharmacy, Taihe County People's Hospital of Anhui Province, Fuyang 236600, Anhui Province, China.
Nan-Nan LiUniversity of Science and Technology of China, The First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, Anhui Province, China.
Zheng LiJiangsu Engineering Research Center of Cardiovascular Drugs Targeting Endothelial Cells, College of Health Sciences, School of Life Sciences, Jiangsu Normal University, Xuzhou 221000, Jiangsu Province, China. lizhengcpu@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this editorial, we comment on the article (

Indexed as

MechanismMulti-targeted tyrosine kinase inhibitorProgrammed cell death protein-1 inhibitorTransarterial chemoembolizationUnresectable hepatocellular carcinoma

Identifiers

PMID39554741
PMCPMC11551641

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.